Karyopharm Therapeutics Competitors

MorphoSys (NASDAQ:MOR) and Karyopharm Therapeutics (NASDAQ:KPTI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares MorphoSys and Karyopharm Therapeutics' revenue, earnings per share and valuation.

MorphoSys has higher revenue and earnings than Karyopharm Therapeutics. MorphoSys is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MorphoSys and Karyopharm Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for MorphoSys and Karyopharm Therapeutics, as provided by MarketBeat.

Karyopharm Therapeutics has a consensus price target of $30.6250, indicating a potential upside of 205.64%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than MorphoSys.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

MorphoSys has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Summary

MorphoSys beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Organogenesis' top-line revenue, earnings per share and valuation.

Organogenesis has higher revenue and earnings than Karyopharm Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Organogenesis' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and Organogenesis, as reported by MarketBeat.com.

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Organogenesis has a consensus target price of $16.50, indicating a potential downside of 27.76%. Given Karyopharm Therapeutics' higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Organogenesis.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Organogenesis shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 57.2% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.

Summary

Organogenesis beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Viela Bio's top-line revenue, earnings per share and valuation.

Viela Bio has higher revenue and earnings than Karyopharm Therapeutics. Viela Bio is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Viela Bio's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and Viela Bio, as reported by MarketBeat.com.

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Viela Bio has a consensus target price of $57.00, indicating a potential upside of 7.53%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Viela Bio.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 47.0% of Viela Bio shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 31.5% of Viela Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Karyopharm Therapeutics (NASDAQ:KPTI) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and OPKO Health's top-line revenue, earnings per share and valuation.

Karyopharm Therapeutics has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and OPKO Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and OPKO Health, as reported by MarketBeat.com.

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. OPKO Health has a consensus target price of $9.00, indicating a potential upside of 115.31%. Given Karyopharm Therapeutics' higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than OPKO Health.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 28.5% of OPKO Health shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 40.9% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.

Summary

OPKO Health beats Karyopharm Therapeutics on 8 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Taro Pharmaceutical Industries' top-line revenue, earnings per share and valuation.

Taro Pharmaceutical Industries has higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and Taro Pharmaceutical Industries, as reported by MarketBeat.com.

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Taro Pharmaceutical Industries has a consensus target price of $81.00, indicating a potential upside of 11.22%. Given Karyopharm Therapeutics' higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Taro Pharmaceutical Industries.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Summary

Taro Pharmaceutical Industries beats Karyopharm Therapeutics on 8 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Corcept Therapeutics' top-line revenue, earnings per share and valuation.

Corcept Therapeutics has higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Corcept Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and Corcept Therapeutics, as reported by MarketBeat.com.

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Corcept Therapeutics has a consensus target price of $24.00, indicating a potential upside of 5.82%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Corcept Therapeutics.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 16.4% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Corcept Therapeutics beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.